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Abstract
Partial nephrectomy is now the preferred surgical option for small renal tumors because it allows nephron
preservation without compromising oncologic clearance. Its outcomes depend on the surgeon’s ability to
continuously identify the edges of the tumor during resection, thus leaving an adequate margin around the
tumor without excessive removal of normal parenchyma, as well as keeping a short ischemic time. Folate
receptors are highly abundant in the normal kidney, and there is a difference in folate receptor expression
between malignant and normal renal tissues. Thus, the use of fluorescent agents that target folate receptors
should result in differential fluorescence between the tumor and surrounding parenchyma during partial
nephrectomy, which, in turn, helps tumor demarcation for identification and resection. A phase 2 study on the
novel use of OTL38 in robot-assisted laparoscopic partial nephrectomy is currently in progress in our
institution. The outcomes of the first three cases have shown the possible advantages of OTL38 in in-
traoperative tumor identification before resection and recognition of residual disease in the surrounding
parenchyma after resection. The tumors typically appeared dark while the surrounding parenchyma showed
brighter fluorescence. Immediately after tumor resection, the margins of all the specimens appeared to have a
uniformly bright fluorescence, suggestive of an intact margin of normal renal parenchyma along the plane of
excision. The pattern of intraoperative fluorescence correlates well with immunohistochemistry. No OTL38-
related adverse effects have been seen among these three patients. We present the outcomes of these three
cases, illustrated with intraoperative and immunohistochemistry images.
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Introduction
Both partial nephrectomy and radical nephrectomyfor small renal tumors show similar oncologic out-
comes.1,2 With increasing evidence showing poorer renal
function and negative cardiovascular effects after radical
nephrectomy, the role of partial nephrectomy as the first-line
surgical option is widely accepted.2,3 Well-performed partial
nephrectomies should include two routine criteria: a negative
margin without excessive removal of surrounding normal
parenchyma and a short warm ischemic time. Various factors
have an impact on the outcomes of partial nephrectomy, in-
cluding surgical approach, surgeons’ experience, and the
availability of new technologies to improve each critical step
during surgery.4,5
Besides three-dimensional laparoscopic vision and added
dexterity, the use of robotic assistance in partial nephrectomy
has the added advantage of having various imaging and filter
systems to possibly help with visual demarcation of tumors
from normal renal parenchyma.6,7 One such example is near-
infrared fluorescence imaging. It involves the activation of an
exogenous fluorescent tracer resulting in light emission in the
near-infrared spectrum, which is then captured by a built-in
charge-coupled device camera.8,9 The differential fluorescent
glow in the tumor and normal renal parenchyma aids tumor
excision with a margin and detection of residual tumors in the
surgical field. There are many exogenous fluorescent tracers
that are suitable for near-infrared fluorescence imaging, with
the most widely studied being indocyanine green.8
Folate targeting involves the use of folate analogs to de-
liver imaging and therapeutic agents to tissues with a high
concentration of folate receptors.10 It has been found that
folate receptors are highly abundant in the normal kidney,
and there is a difference in folate receptor expression between
malignant and normal renal tissues.11,12 The use of a folate
analog conjugated to a fluorescent tracer during partial ne-
phrectomy may therefore help to identify the local extent of
the tumor immediately before surgical excision. The concept
of folate-targeted intraoperative fluorescence has been ap-
plied effectively in the surgical management of ovarian
cancer.13 Folate receptors are highly expressed in ovarian
tumors but minimally within normal ovarian tissues, result-
ing in the intraoperative finding of brightly fluorescent tu-
mors surrounded by normal tissues without fluorescence. In
contrast, folate receptors are highly expressed in normal
kidneys, but less so within renal tumors. Therefore, the pat-
tern of intraoperative fluorescence in partial nephrectomy
may be different from that in ovarian cancer surgery.
We are currently performing a phase 2 nonrandomized
study on the novel use of folate-targeted intraoperative
fluorescence in renal cancer, and we are reporting the out-
comes of the first three cases of partial nephrectomy in this
ongoing study.
Materials and Methods
The institutional review board approved this study
(protocol number: 1511879268, approval date: December
16, 2015). The entire phase 2 study involves a total of 20
patients in 2 arms, with 10 having localized renal-cell
carcinoma (RCC) for robot-assisted laparoscopic partial
nephrectomy (RALPN) and 10 having locally advanced or
metastatic RCC for open or robot-assisted laparoscopic
radical nephrectomy. The main objective is to explore the
use of folate-targeted intraoperative fluorescence to iden-
tify the margins of resection in RALPN and to identify
lymph nodes or other metastases in radical nephrectomy.
For the purpose of this article reporting the outcomes of the
first three cases of RALPN, we shall elaborate on the study
protocol in the RALPN arm. Table 1 illustrates the inclu-
sion and exclusion criteria.
Within 90 days before surgery, the patients attend a
screening visit, during which they give informed consent for
the study. Their demographics, height and weight, medical
history, and physical examination findings are recorded.
Complete blood count, serum electrolyte levels, and renal
function are also measured.
On the day of surgery, a single dose of OTL38 (On Target
Laboratories LLC., West Lafayette, IN) at 0.025 mg/kg and
a single dose of 25 mg diphenhydramine are administered
Table 1. Inclusion and Exclusion Criteria for the Partial Nephrectomy Arm of the Study
Inclusion criteria Exclusion criteria
At least 18 years old Known anaphylactic or allergic reactions to folate and its
analogs
Proven or suspected diagnosis of cT1-2 RCC by CT
assessment
Known sensitivity to fluorescent light
Scheduled for partial nephrectomy Renal impairment (baseline GFR below 50 mL/min/1.73 m2)
Expected survival of at least 3 months Hepatic disorders (CTCAE version 4 definition ‡ grade 2)
Good performance status (ECOG £1) Brain metastases
Negative serum or urine pregnancy test within 24 hours
before partial nephrectomy (for females of child-bearing
age)
Participation in another investigational drug trial within
30 days before partial nephrectomy
Willingness to participate after the process of informed
consent
Any medical conditions that, in the opinion of the
investigators, could potentially jeopardize patient’s
safety, limit the patient’s ability to complete the study, or
compromise the objectives of the study
CTCAE =Common Terminology Criteria for Adverse Events; ECOG =Eastern Cooperative Oncology Group; GFR= glomerular
filtration rate; RCC = renal-cell carcinoma.
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intravenously within 2 hours before skin incision. OTL38 is
constructed from folic acid linked by its c-carboxyl and a
short spacer to an indocyanine green-related near-infrared
dye termed SO456.14 It targets folate receptor alpha (FRa),
which is highly expressed in the kidney. Upon excitation, it
emits light in the near-infrared spectrum. During RALPN,
the da Vinciª Fluorescence Imaging Vision System (In-
tuitive Surgical, Inc., Sunnyvale, CA) is used to identify
tumor margins with visible and fluorescent light immedi-
ately before excision and to identify any residual disease
immediately after excision. Video and still images are taken
in visible and fluorescent light immediately before and after
excision. Upon excision, the tumor specimen is sent to the
pathologist for inking and sectioning into 5-mm-thick slices
for macroscopic assessment of the margin status. Again,
video and still images of the tumor specimen in visible and
fluorescent lights are taken.
At the end of surgery, the surgeon completes a ques-
tionnaire describing the usefulness of folate-targeted in-
traoperative fluorescence for tumor identification and
excision. A coinvestigator, who is a blinded surgeon un-
involved with the case, views the visible and fluorescent
light images and completes a questionnaire to assess in-
terobserver agreement. Any adverse effects related to the
use of OTL38, such as hypersensitivity or injection site
inflammatory reactions, are noted.
Postoperatively, the patients are monitored as per standard
clinical practice. Serial assessments with complete blood
counts, serum electrolytes, and renal functions are performed.
A review visit at 1 month after surgery provides an eventual
assessment of surgical outcomes and identifies any delayed
adverse effects from the use of OTL38. The final histopa-
thology of the tumor specimen is also noted. Figure 1 sum-
marizes the study protocol on the use of OTL38 in RALPN.
FIG. 1. Study protocol on the use
of OTL38 in robot-assisted laparo-
scopic partial nephrectomy.
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The primary objective of this study is to explore the use
of OTL38 during RALPN and the pattern of fluorescence
in the tumor and surrounding parenchyma. The second-
ary objectives include correlation between intraoperative
tumor fluorescence and FRa status of tumor specimens by
immunohistochemistry, assessment of the usefulness of
OTL38 in intraoperative identification of tumor margins by
the operating surgeon, assessment of any interobserver
variations by a blinded coinvestigator, and assessment of
the clinical safety of OTL38 among RCC patients up to 1
month after surgery.
Results
So far, three patients have completed treatment and
follow-up as per study protocol in the RALPN arm in this
ongoing study.
All three patients were men and ranged from 50 to 70
years of age. They presented with incidental small renal
masses 15 to 22 mm in largest diameter. Figure 2 shows
the transverse and coronal CT images representative of
their renal masses. All patients received OTL38 and
underwent RALPN as per study protocol. Fluorescent
lights were used to identify tumor margins immediately
before excision and to look for possible residual disease in
the resection bed immediately after excision. All tumors
were excised by sharp dissection with scissors under
visible light and near-infrared imaging. A two-layered
renorrhaphy was routinely performed for hemostasis and
repair of the defect after excision in all three patients. The
mean length of hospital stay was 2 days (range: 1–3 days).
The pattern of intraoperative fluorescence among all three
patients was similar. All renal tumors did not appear fluo-
rescent, whereas the surrounding parenchyma showed mild
fluorescence in the first patient and bright fluorescence in the
second and third patients. Figure 3 shows the pattern of in-
traoperative fluorescence in the patients.
The complete lack of fluorescence in the renal tumors
surrounded by fluorescent parenchyma served as a good
indicator for the tumor margins in all the three patients.
During excision of the tumors, intermittent switching from
visible to fluorescent light also helped in confirming the
FIG. 2. CT images of the pa-
tients, with tumors indicated by
arrows. (A, B) Transverse and
coronal views of renal tumor in the
first patient. (C, D) Transverse and
coronal views of renal tumor in the
second patient. (E, F) Transverse
and coronal views of renal tumor in
the third patient.
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correct depth of excision. Warm ischemic time, measured
from the clamping of the renal arteries to the release of
clamps after the first layer of renorrhaphy, ranged from
10 to 16 minutes. The estimated blood loss ranged from
50 to 200 mL.
Immediately after tumor excision, the margin of the
specimen appeared to have a uniformly bright fluores-
cence, suggestive of an intact margin of normal renal
parenchyma around the plane of excision. Figure 4 shows
the cut surfaces of the tumors under visible and fluo-
rescent light.
Upon histologic examination of the tumor specimens,
the first and second patient showed Fuhrman grade 2
clear-cell RCC with uninvolved margins, and the third
patient showed Fuhrman grade 2 type 1 papillary RCC
with uninvolved margins. Immunohistochemistry showed
consistent correlation with the pattern of intraoperative
fluorescence in all the three patients. Only 10% to 30%
of tumor cells were stained for FRa, but the surround-
ing renal parenchyma demonstrated strong staining, es-
pecially along the luminal surface of the renal tubular
epithelium. Figure 5 shows the immunohistochemistry
results of the patients.
All the three patients had an uneventful postoperative re-
covery and did not show any OTL38-related adverse effects
up to 1 month after the surgery. There were no significant
perioperative changes in serum electrolyte levels and renal
function. Table 2 summarizes the demographics and out-
comes of our three patients.
Discussion
All forms of cancer surgery with the intent to cure should
focus on oncologic clearance, and partial nephrectomy for
renal tumors is no exception. Partial nephrectomy is advan-
tageous over radical nephrectomy for small renal tumors
because of nephron preservation, yet it remains noninferior
in terms of oncologic outcomes.1,2 Various modalities are
used to increase the negative margin rates during partial
nephrectomy. These include intraoperative imaging such as
ultrasonography, pathologic assessments such as frozen
section, and the use of fluorescent tracers such as in-
docyanine green to pinpoint the tumor edge.7,9,15–19 When
used singly or in combination, these modalities provide in-
traoperative assurance to the surgeon that tumor resection is
complete and residual disease is unlikely. The ability to
FIG. 3. Pattern of intraoperative
fluorescence of the patients. Tu-
mors are highlighted with oval
white lines. (A, B) Renal tumor and
surrounding parenchyma of the first
patient under visible and fluores-
cent lights. (C, D) Renal tumor and
surrounding parenchyma of the
second patient under visible and
fluorescent lights. (E, F) Renal
tumor and surrounding parenchyma
of the third patient under visible
and fluorescent lights.
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continuously and accurately identify the tumor margin during
partial nephrectomy also reduces unnecessary pauses to con-
firm the plane of resection, thus potentially avoiding pro-
longed arterial clamping and warm ischemia. Warm ischemic
time has a direct impact on postoperative renal function
which, in turn, correlates with cardiovascular complications
and overall survival.20
Advances in biomolecular research have also contributed
to improved outcomes of cancer surgery. The expressions of
FRa in various human cancer and normal tissues have been
delineated.11,12 There are differences in expression between
cancer and normal tissues in several organs, including ovary
and kidney. Such discrepancies in FRa expression can be
exploited clinically, such that folate analogs conjugated to
various contrast agents show different degrees of binding to
normal and malignant tissues. The recent use of folate-
targeted intraoperative fluorescence with OTL38 among pa-
tients with ovarian cancer has shown encouraging results,
allowing resection of an additional 29% of malignant lesions
that were previously unidentifiable by inspection or palpa-
tion.13 Ovarian tumors and metastatic deposits appeared
fluorescent and were easily located during surgery.
In the human kidney, FRa expression reaches 100% at the
apical surface of the proximal tubules, where it plays the
physiologic role of folate reabsorption.21 Renal carcinoma,
whether in vivo or in established cell lines, shows a lower
expression of FRa.11,12 The pattern of intraoperative fluo-
rescence in our three patients appeared to be consistent with
the difference in FRa expression in normal and malignant
renal tissues and facilitated the identification of the local
extents of the tumors. The bright fluorescence along the cut
surfaces of the tumors at the end of resection could be in-
tuitively recognized by the surgeon as an indication of ad-
equate margin. While the study is still ongoing, such initial
findings seem to indicate that folate-targeted intraoperative
fluorescence with OTL38 is feasible and facilitates the
recognition and resection of small tumors in partial ne-
phrectomy. Upon completion of the entire phase 2 study, we
shall be able to report the negative margin rate, warm is-
chemic time, and other operative parameters associated with
the use of OTL38.
The choice of FRa-targeting fluorescent tracer for partial
nephrectomy should be carefully considered. The differ-
ence in fluorescence between renal parenchyma and tumor
should be as distinct as possible. In our three cases of
partial nephrectomy where the tumors had no fluorescence,
bright fluorescence in the renal parenchyma would be
ideal. We had access to two tracers, namely EC17 and
FIG. 4. Cut surfaces of the tu-
mors immediately after excision.
(A, B) Visible and fluorescent light
images of the first patient. (C, D)
Visible and fluorescent light im-
ages of the second patient. (E, F)
Visible and fluorescent light im-
ages of the third patient.
Shum, et al.; Journal of Endourology Case Reports 2016, 2.1
http://online.liebertpub.com/doi/10.1089/cren.2016.0104
194
OTL38, and both contain the same folate ligand for binding
with FRa. They differ in the fluorochrome, with EC17
carrying fluorescein, which fluoresces with a peak wave-
length of 510 nm, and OTL38 carrying indocyanine green,
which fluoresces with a peak wavelength of 794 nm.14
Comparison between the two tracers showed that OTL38
has the advantages of deeper tissue penetration, reduced
scattering, and reduced autofluorescence. Most impor-
tantly, OTL38 fluoresces in the kidneys, whereas EC17
does not.14 Previous experience with EC17 for partial ne-
phrectomy had problems with autofluorescence and poor
tissue penetration, and tumor fluorescence was only present
in 50% of cases.22 Therefore, OTL38 seemed to be a more
suitable tracer.
Immunohistochemistry results from our three patients
confirmed significantly lower expression of FRa in tumors
than in normal parenchyma. Both the intensity and the den-
sity of stains were much lower within tumors, consistent with
the observed difference in intraoperative fluorescence be-
tween normal and malignant renal tissues. Such immuno-
histochemistry also concurs with the findings from previous
studies using polymerase chain reaction or radioligand
binding assay to determine FRa expression in frozen human
tissues and established cell lines.11,12 With two of our pa-
tients having clear-cell RCC and one having papillary RCC, it
seems that both histologic cell types are poor in FRa ex-
pression compared with normal renal parenchyma.
Interestingly, while our patients demonstrated poor ex-
pression of FRa in the small localized renal tumors, a pre-
vious study showed much higher expression of folate
receptors in metastatic RCC. Using an imaging agent that
consisted of folate conjugated to technetium-99m, 74% of
metastatic RCC showed mild to marked uptake.23 The dif-
ference in folate receptor expression between small localized
renal tumors and metastatic RCC raises the possibility for
folate targeting to be used for prognostication in RCC.
Based on the current medical literature, the most common
OTL38-related adverse event is hypersensitivity reaction,
and its occurrence seems to be dose related.13 We chose the
dose of 0.025 mg/kg after reviewing safety and efficacy data
from previous studies.13,24 The concurrent administration of
an antihistamine agent was intended to further reduce the risk
of hypersensitivity reactions among our study patients. There
were no OTL38-related adverse events observed in all of our
patients for up to a month after the surgery. However, with
outcomes from only three patients, we are unable to comment
on the clinical safety of OTL38 among patients with renal
tumors at the current moment.
FIG. 5. Immunohistochemistry
of the three patients showing con-
sistently strong staining for FRa in
normal renal parenchyma, but
minimal staining in RCC. (A, B)
Staining for FRa in tumor and renal
parenchyma of the first patient. (C,
D) Staining for FRa in tumor and
renal parenchyma of the second
patient. (E, F) Staining for FRa in
tumor and renal parenchyma of the
third patient. FRa, folate receptor
alpha; RCC, renal-cell carcinoma.
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Conclusion
The outcomes of the initial three patients seemed
encouraging, with easy tumor identification and resection due
to the clearly observed difference in intraoperative fluores-
cence in renal tumors and their surrounding renal parenchyma.
We also demonstrated a close correlation between in-
traoperative fluorescence with OTL38 and FRa staining on
immunohistochemistry. As more patients complete the study,
we hope to draw more definite conclusions on the use of
OTL38 for RALPN, including its intraoperative fluorescence
pattern, impact on warm ischemic time and negative margin
rate, and adverse effects. We also hope to confirm if these
outcomes may be affected by other factors, such as tumor cell
types and other patient-dependent variables.
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RCC ¼ renal-cell carcinoma
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